奈拉滨、强化L-天冬酰胺酶及延长鞘内治疗用于儿童及年轻成人初诊T细胞急性淋巴细胞白血病(ALL-T11):一项全国性、多中心、2期试验,含极高危组随机化
ALL-T11是一项全国性、多中心、2期试验,纳入349例初诊T细胞急性淋巴细胞白血病患者(诊断时年龄<25岁),采用AIEOP-BFM-ALL 2000骨架化疗,高危和极高危患者加用奈拉滨(650 mg/m2/天,5天),极高危组随机分配至A组(BFM为基础的大块治疗)或B组(另一种含大剂量地塞米松的大块治疗)。主要终点为整个队列的3年无事件生存率及极高危组随机分组间微小残留病消失比例。
要点
- 3年无事件生存率为86.4%(95% CI 82.3-89.7%),3年总生存率为91.3%(87.7-93.8%)。
- 极高危组微小残留病消失比例:A组0.86(12/14,95% CI 0.57-0.98)vs B组0.50(6/12,0.21-0.79)。
- 3级外周运动神经病变见于11/349例(3%),感觉神经病变见于6/349例(2%)。
核心结论
- ALL-T11方案在限制颅脑放疗和造血干细胞移植使用的情况下,产生了令人鼓舞的结局,且毒性可接受。
研究设计与样本
- 全国性、多中心、2期试验,由日本儿童癌症组和日本成人白血病研究组实施,纳入349例初诊T细胞急性淋巴细胞白血病患者(诊断时年龄<25岁)。
- 根据泼尼松反应、中枢神经系统状态和巩固治疗末微小残留病将患者分为标危、高危和极高危组。
- 极高危组按1:1随机分配至A组(BFM为基础的大块治疗)和B组(另一种含大剂量地塞米松的大块治疗),按医院、年龄(≥18岁或<18岁)和诱导末骨髓原始细胞百分比M1(<5%)或M2(≥5%,<25%)+M3(≥25%)分层。
主要发现
- 2011年12月1日至2017年11月30日,349例 eligible 患者中位年龄9岁(IQR 6-13),238例(68%)为男性,28例(8%)为CNS3状态。
- 风险分层:标危168例(48%),高危103例(30%),极高危39例(11%),无风险39例(11%)。
- 诱导缓解治疗后复合完全缓解率为89%(298/335例)。
- 333例患者中35例(10%)接受了造血干细胞移植。
- 中位随访5.2年(IQR 3.6-6.7),3年无事件生存率为86.4%(95% CI 82.3-89.7%),3年总生存率为91.3%(87.7-93.8%)。
关键数值与推荐
- 奈拉滨650 mg/m2/天,共5天,用于高危和极高危患者。
- 地塞米松10 mg/m2/天:<10岁患者用3周;≥10岁患者用2周(含7天停药间隔),替代泼尼松。
- 颅脑放疗仅限于诊断时存在明显中枢神经系统疾病(CNS3;>5个白细胞/μL且见原始细胞)的患者;无中枢神经系统疾病证据的患者接受延长三联鞘内治疗。
- 仅极高危患者计划接受造血干细胞移植。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: T-cell acute lymphoblastic leukaemia has distinct biological characteristics and a poorer prognosis than B-cell precursor acute lymphoblastic leukaemia. This trial aimed to reduce the rate of radiation and haematopoietic stem-cell transplantation (HSCT) while improving outcomes by adding nelarabine, intensified L-asparaginase, and protracted intrathecal therapy in the Berlin-Frankfurt-Münster (BFM)-type treatment. METHODS: In this nationwide, multicenter, phase 2 trial, we enrolled patients with newly diagnosed T-cell acute lymphoblastic leukaemia (age <25 years at diagnosis) conducted by Japan Children's Cancer Group and Japan Adult Leukemia Study Group. Patients were stratified into standard-risk, high-risk, and very-high-risk groups according to prednisolone response, CNS status, and end-of-consolidation minimal residual disease. We used the Associazione Italiana di Ematologia Oncologia Pediatrica (AIEOP)-BFM-ALL 2000-backbone chemotherapy. Nelarabine (650 mg/m2 per day for 5 days) was given to high-risk and very high-risk patients. All patients received, until the measurement of end-of-consolidation minimal residual disease, an identical therapy schedule, which included the prednisolone pre-phase remission induction therapy with dexamethasone (10 mg/m2 per day, for 3 weeks [for patients <10 years] or for 2 weeks including a 7-day off interval [for patients ≥10 years]) instead of prednisolone, and consolidation therapy added with Escherichia coli-derived L-asparaginase. On the basis of the stratification, patients received different intensities of treatment; L-asparaginase-intensified standard BFM-type therapy for standard risk and nelarabine-added high risk BFM-type therapy for high risk. In the very high-risk group, patients were randomly assigned (1:1) to group A (BFM-based block therapy) and group B (another block therapy, including high-dose dexamethasone) stratified by hospital, age (≥18 years or <18 years), and end-of-induction bone marrow blast percentage of M1 (<5%) or M2 (≥5%, <25%)+M3 (≥25%). Cranial radiotherapy was limited to patients with overt CNS disease at diagnosis (CNS3; >5 white blood cells per μL with blasts) and patients with no evidence of CNS disease received protracted triple intrathecal therapy. Only very high-risk patients were scheduled to receive HSCT. The primary endpoint was 3-year event-free survival for the entire cohort and the proportion of patients with disappearance of minimal residual disease between randomly assigned groups A and B in the very high-risk group. Secondary endpoints were overall survival, remission induction rate, and occurrence of adverse events. 3 years after the completion of patient accrual, a primary efficacy analysis was performed in the full analysis set and the per-protocol set. This study is registered with the Japan Registry of Clinical Trials, jRCTs041180145. FINDINGS: Between Dec 1, 2011, and Nov 30, 2017, of 349 eligible patients (median age 9 years [IQR 6-13]), 238 (68%) were male, and 28 (8%) patients had CNS3 status. 168 (48%) patients were stratified as standard risk, 103 (30%) as high risk, 39 (11%) as very high risk, and 39 (11%) as no risk (patients who had off protocol treatment before risk assessment. The composite complete remission (complete remission plus complete remission in suppression) rate after remission induction therapy was 89% (298 of 335 patients). HSCT was performed in 35 (10%) of 333 patients. With a median follow-up of 5·2 years (IQR 3·6-6·7), 3-year event-free survival was 86·4% (95% CI 82·3-89·7%) and 3-year overall survival was 91·3% (87·7-93·8%). The proportion of minimal residual disease disappearance was 0·86 (12 of 14 patients; 95% CI 0·57-0·98) in group A and 0·50 (6 of 12 patients, 0·21-0·79) in group B. Grade 3 peripheral motor neuropathy was seen in 11 (3%) of 349 patients and sensory neuropathy was seen in 6 (2%) patients. The most common grade 3 or worse adverse event was febrile neutropenia (294 [84%] of 349 patients). Treatment-related death occurred in three patients due to sepsis, gastric perforation, or intracranial haemorrhage during remission induction. INTERPRETATION: The ALL-T11 protocol produced encouraging outcomes with acceptable toxicities despite limited cranial radiotherapy and HSCT use. FUNDING: Ministry of Health, Labor and Welfare of Japan, and Japan Agency for Medical Research and Development. TRANSLATION: For the Japanese translation of the abstract see Supplementary Materials section.
引用
- Sato A, Hatta Y, Imai C, et al. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group. Lancet Haematol. 2023. PMID: 37167992. doi:10.1016/S2352-3026(23)00072-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。